Cordis Corporation Release: First Patient Enrolled in Study Evaluating S.M.A.R.T.(R) Nitinol Self-Expandable Stent System in Leg Disease

WARREN, N.J.--(BUSINESS WIRE)--Cordis Corporation today announced the first patient enrollment in the STROLL trial, which will evaluate the safety and efficacy of the S.M.A.R.T. ® Nitinol Self-Expandable Stent System in treating patients with obstructive superficial femoral artery (SFA) disease, also known as SFA atherosclerosis. The STROLL trial will support a planned PMA filing with the U.S. Food and Drug Administration that, if approved, will allow Cordis to market the S.M.A.R.T. ® Stent for this important indication.